Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Fig. 1

The study flow diagram. In all, 140 patients who received carboplatin-based chemotherapy were analyzed from three multicenter, prospective, single-arm, open-label, phase II studies. 5-HT3RA, 5-hydroxytryptamine-3 receptor antagonist; DEX, dexamethasone; NK1RA, neurokinin-1 receptor antagonist; OLZ, olanzapine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us